On October 17, Hansoh Pharmaceutical (03692) announced that it had entered into a licensing agreement with F. Hoffmann-La Roche Ltd. (a subsidiary of Roche). Under the agreement, Hansoh Pharmaceutical 's wholly-owned subsidiaries, Shanghai Hansoh Biopharmaceutical Technology Co., Ltd. and Changzhou Hengbang Pharmaceutical Co., Ltd., will grant the licensee an exclusive global license (excluding Mainland China, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize HS-20110.
Hansoh Pharma will receive an upfront payment of $80 million and is eligible to receive up to $1.45 billion in milestone payments based on the product's development, regulatory approval, and commercialization progress, as well as tiered royalties on potential future product sales.
The product is an investigational CDH17-targeting antibody-drug conjugate (ADC) currently in global Phase I clinical trials in China and the United States for the treatment of colorectal cancer and other solid tumors. The Board of Directors believes that this license agreement is in the best interests of the Company and its shareholders as a whole and will maximize the scientific and commercial value of the Group's technology platform.

https://finance.eastmoney.com/a/202510173537020357.html